AR017019A1 - COMPOUNDS DERIVED FROM 2- (4-ARIL OR HETEROARILPIPERAZIN-1-ILMETIL) -1H-INDOL, COMPOSITIONS AND ITS USE IN THE MANUFACTURE OF MEDICINES - Google Patents
COMPOUNDS DERIVED FROM 2- (4-ARIL OR HETEROARILPIPERAZIN-1-ILMETIL) -1H-INDOL, COMPOSITIONS AND ITS USE IN THE MANUFACTURE OF MEDICINESInfo
- Publication number
- AR017019A1 AR017019A1 ARP980104021A ARP980104021A AR017019A1 AR 017019 A1 AR017019 A1 AR 017019A1 AR P980104021 A ARP980104021 A AR P980104021A AR P980104021 A ARP980104021 A AR P980104021A AR 017019 A1 AR017019 A1 AR 017019A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- cyano
- nitrogen
- trifluoromethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 125000001246 bromo group Chemical group Br* 0.000 abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Substances 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 1
- 101100495911 Arabidopsis thaliana CHR10 gene Proteins 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Un compuesto derivado de 2-(4-aril o heteroarilpiperazin-1-ilmetil)-1H-indol de formula (I) o sal farmacéuticamente aceptable del mismo, donde lalínea discontinua representa un doble enlace opcional; a es 0 o 1, en el que cuando a es 0, X puedeforma r un doble enlace opcional con el carbono adyacente aV; V es CHR10, en el que R10 es hidrogeno o alquilo C1-6; T es nitrogeno o CH; X es nitrogeno o CR11, en el que R11 es hidrogeno, alquilo C1-6, alcoxi C1-6,hidroxi o ciano; Y y Z son cadauno de el los independientemente nitrogeno o CR12, en el que R12 es hidrogeno, cloro, bromo, trifluorometilo, trifluorometoxi,ciano, alcoxi C1-6 o alquilo C1-6; R1 es hidrogeno, fluoro, cloro, bromo, trifluorometilo, trifluorometoxi, ciano o alquiloC1-6; R2, R6, R7, R8 y R9 estáncada uno de ellos independientemente seleccionados entre hidrogeno, fluoro, cloro, bromo, trifluorometilo, trifluorometoxi, ciano, alcoxi C1-6 y alquiloC1-6; R3 y R4 son cada uno de ellos independientemente hidrogeno oalquilo C1 -6; y R5 es hidrogeno, alcoxi C1-6, trifluorometilo, ciano, alquilo C1-6 oR13CO, en el que R13 es amino, alquil C1-6-amino, (alquilo C1-6)2 amino, alquilo C1-6, arilo C6-10; o cuando a es 1, R1 y R10 se pueden unir con loscarbonos a losque están uni dos para formar un compuesto de formula (II) en la que las líneas discontinuas representan enlaces opcionales; T, X, Y, Z, R2, R3,R4, R5, R6, R7, R8 y R9 son lo definido anteriormente; b es 0 o 1; y A y B son cada uno de ellosindependientemente CH, CH2,oxígeno, azufre, NH o nitrogeno;con la condicion de que cuando X es nitrogeno, el doble enlace opcional entre X y V no existe; con la condicion de que cuando b es 0, el doble enlaceopcional entre A y B no existe; y con lacondicion de que cuando b es 1, A y B no pueden ser ninguno de ellos oxígeno o azufre. Los compuestos antesmencionados son utiles para el tratamiento de trastornos del sistema de la dopamina. Se describen también composiciones y el uso de loscompuestos enla manufactura de medicamentos.A compound derived from 2- (4-aryl or heteroarylpiperazin-1-ylmethyl) -1H-indole of formula (I) or pharmaceutically acceptable salt thereof, where the broken line represents an optional double bond; a is 0 or 1, where when a is 0, X can form an optional double bond with the carbon adjacent to V; V is CHR10, wherein R10 is hydrogen or C1-6 alkyl; T is nitrogen or CH; X is nitrogen or CR11, wherein R11 is hydrogen, C1-6 alkyl, C1-6 alkoxy, hydroxy or cyano; Y and Z are each independently of the nitrogen or CR12, wherein R12 is hydrogen, chlorine, bromine, trifluoromethyl, trifluoromethoxy, cyano, C1-6 alkoxy or C1-6 alkyl; R1 is hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano or C1-6 alkyl; R2, R6, R7, R8 and R9 are one of them independently selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, trifluoromethoxy, cyano, C1-6 alkoxy and C1-6 alkyl; R3 and R4 are each independently hydrogen or C1-6alkyl; and R5 is hydrogen, C1-6 alkoxy, trifluoromethyl, cyano, C1-6 alkyl or R13CO, wherein R13 is amino, C1-6 alkyl, (C1-6 alkyl) 2 amino, C1-6 alkyl, C6 aryl -10; or when a is 1, R1 and R10 can be joined with the carbons to which they are joined to form a compound of formula (II) in which the dashed lines represent optional bonds; T, X, Y, Z, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined above; b is 0 or 1; and A and B are each independently CH, CH2, oxygen, sulfur, NH or nitrogen, with the proviso that when X is nitrogen, the optional double bond between X and V does not exist; with the proviso that when b is 0, the optional double bond between A and B does not exist; and with the proviso that when b is 1, A and B cannot be any of them oxygen or sulfur. The aforementioned compounds are useful for the treatment of disorders of the dopamine system. Compositions and the use of the compounds in the manufacture of medicaments are also described.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5576497P | 1997-08-15 | 1997-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017019A1 true AR017019A1 (en) | 2001-08-22 |
Family
ID=22000003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980104021A AR017019A1 (en) | 1997-08-15 | 1998-08-13 | COMPOUNDS DERIVED FROM 2- (4-ARIL OR HETEROARILPIPERAZIN-1-ILMETIL) -1H-INDOL, COMPOSITIONS AND ITS USE IN THE MANUFACTURE OF MEDICINES |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1003739A2 (en) |
| JP (1) | JP2002536291A (en) |
| KR (1) | KR20010022507A (en) |
| CN (1) | CN1265660A (en) |
| AP (1) | AP9801321A0 (en) |
| AR (1) | AR017019A1 (en) |
| AU (1) | AU8457298A (en) |
| BG (1) | BG104069A (en) |
| BR (1) | BR9811557A (en) |
| CA (1) | CA2297486C (en) |
| CO (1) | CO4960656A1 (en) |
| DZ (1) | DZ2583A1 (en) |
| EA (1) | EA200000023A1 (en) |
| HR (1) | HRP980441A2 (en) |
| HU (1) | HUP0003425A3 (en) |
| ID (1) | ID23803A (en) |
| IL (1) | IL133960A0 (en) |
| IS (1) | IS5336A (en) |
| MA (1) | MA24632A1 (en) |
| NO (1) | NO20000722D0 (en) |
| OA (1) | OA11286A (en) |
| PA (1) | PA8457001A1 (en) |
| PE (1) | PE106299A1 (en) |
| PL (1) | PL338947A1 (en) |
| SK (1) | SK1352000A3 (en) |
| TN (1) | TNSN98151A1 (en) |
| TR (1) | TR200000414T2 (en) |
| UY (1) | UY25144A1 (en) |
| WO (1) | WO1999009025A2 (en) |
| ZA (1) | ZA987304B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE04588B1 (en) * | 1997-10-27 | 2006-02-15 | Neurosearch A/S | Heteroaryl diazacycloalkanes as cholinergic ligands for acetylcholine nicotine receptors, their use as pharmaceuticals and pharmaceutical composition containing them |
| EP0953567A3 (en) * | 1998-04-29 | 2003-04-02 | Pfizer Products Inc. | Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity |
| DE60011817T2 (en) | 1999-12-30 | 2005-07-14 | H. Lundbeck A/S | 4-PHENYL-1-PIPERAZINYL, -PIPERIDINYL AND -ETRAHYDROPYRIDYL DERIVATIVES |
| GB0017952D0 (en) * | 2000-07-22 | 2000-09-13 | Univ Manchester | Treatment of dyskinesia |
| EP1177792A3 (en) | 2000-07-27 | 2002-10-23 | Pfizer Products Inc. | Dopamine D4 Ligands for the treatment of novelty-seeking disorders |
| US6803362B2 (en) | 2001-03-09 | 2004-10-12 | Ortho-Mcneil Pharmaceutical Inc. | Heterocyclic compounds |
| PL377087A1 (en) | 2002-09-06 | 2006-01-23 | Janssen Pharmaceutica, N.V. | Heterocyclic compounds |
| WO2004108671A1 (en) * | 2003-06-06 | 2004-12-16 | Suven Life Sciences Limited | Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them |
| EP1731505B1 (en) | 2004-03-30 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| US7618980B2 (en) | 2004-07-14 | 2009-11-17 | Bristol-Myers Squibb Company | Pyrrolo(oxo)quinolines as 5HT ligands |
| US7572805B2 (en) | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
| JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Fast Dissociting Dopamine 2 Receptor Antagonists |
| JO2642B1 (en) * | 2006-12-08 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Fast Dissociating Dopamine 2 Receptor Antagonists |
| JO2849B1 (en) * | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Fast -Dissociating Dopamine 2 Receptor Antagonists |
| MX2009011416A (en) | 2007-04-23 | 2009-11-05 | Janssen Pharmaceutica Nv | Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists. |
| CN101663292A (en) | 2007-04-23 | 2010-03-03 | 詹森药业有限公司 | 4-Alkoxypyridazine derivatives as rapidly dissociating dopamine 2 receptor antagonists |
| BRPI0915834A2 (en) | 2008-07-03 | 2015-11-03 | Janssen Pharmaceutica Nv | Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists |
| AU2009275887B2 (en) | 2008-07-31 | 2013-06-20 | Janssen Pharmaceutica Nv | Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists |
| CN109843872B (en) * | 2017-09-20 | 2022-08-30 | 杭州英创医药科技有限公司 | Polycyclic compounds as IDO inhibitors and/or IDO-HDAC dual inhibitors |
| WO2021216665A1 (en) * | 2020-04-22 | 2021-10-28 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB944443A (en) * | 1959-09-25 | 1900-01-01 | ||
| ATE148464T1 (en) * | 1991-07-03 | 1997-02-15 | Upjohn Co | SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICAL PREPARATIONS |
| JPH05255089A (en) * | 1991-12-18 | 1993-10-05 | Sanwa Kagaku Kenkyusho Co Ltd | Antiviral agent |
| JPH08502958A (en) * | 1992-10-23 | 1996-04-02 | メルク シヤープ エンド ドーム リミテツド | Dopamine receptor subtype ligand |
| GB9305644D0 (en) * | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| US5576336A (en) * | 1993-03-18 | 1996-11-19 | Merck Sharp & Dohme Limited | Indole derivatives as dopamine D4 antagonists |
| US5814644A (en) * | 1993-04-15 | 1998-09-29 | Merck Sharp & Dohme, Ltd. | Indole derivatives as dopamine D4 antagonists |
| DE4414113A1 (en) * | 1994-04-22 | 1995-10-26 | Merck Patent Gmbh | 3-indolylpiperidines |
| TW406075B (en) * | 1994-12-13 | 2000-09-21 | Upjohn Co | Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds |
| ZA968661B (en) * | 1995-11-17 | 1998-04-14 | Upjohn Co | Oxazolidinone antibacterial agent with tricyclic substituents. |
| TW504510B (en) * | 1996-05-10 | 2002-10-01 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives |
-
1998
- 1998-08-05 IL IL13396098A patent/IL133960A0/en unknown
- 1998-08-05 AU AU84572/98A patent/AU8457298A/en not_active Abandoned
- 1998-08-05 CN CN98807831A patent/CN1265660A/en active Pending
- 1998-08-05 BR BR9811557-0A patent/BR9811557A/en not_active IP Right Cessation
- 1998-08-05 JP JP2000509706A patent/JP2002536291A/en active Pending
- 1998-08-05 EA EA200000023A patent/EA200000023A1/en unknown
- 1998-08-05 AP APAP/P/1998/001321A patent/AP9801321A0/en unknown
- 1998-08-05 EP EP98935229A patent/EP1003739A2/en not_active Withdrawn
- 1998-08-05 PL PL98338947A patent/PL338947A1/en unknown
- 1998-08-05 KR KR1020007001093A patent/KR20010022507A/en not_active Ceased
- 1998-08-05 HU HU0003425A patent/HUP0003425A3/en unknown
- 1998-08-05 WO PCT/IB1998/001198 patent/WO1999009025A2/en not_active Ceased
- 1998-08-05 CA CA002297486A patent/CA2297486C/en not_active Expired - Fee Related
- 1998-08-05 SK SK135-2000A patent/SK1352000A3/en unknown
- 1998-08-05 ID IDW20000197A patent/ID23803A/en unknown
- 1998-08-05 TR TR2000/00414T patent/TR200000414T2/en unknown
- 1998-08-10 PE PE1998000717A patent/PE106299A1/en not_active Application Discontinuation
- 1998-08-10 PA PA19988457001A patent/PA8457001A1/en unknown
- 1998-08-12 MA MA25210A patent/MA24632A1/en unknown
- 1998-08-12 DZ DZ980193A patent/DZ2583A1/en active
- 1998-08-12 TN TNTNSN98151A patent/TNSN98151A1/en unknown
- 1998-08-13 AR ARP980104021A patent/AR017019A1/en unknown
- 1998-08-14 CO CO98046788A patent/CO4960656A1/en unknown
- 1998-08-14 HR HR60/055,764A patent/HRP980441A2/en not_active Application Discontinuation
- 1998-08-14 ZA ZA9807304A patent/ZA987304B/en unknown
- 1998-08-17 UY UY25144A patent/UY25144A1/en not_active Application Discontinuation
-
2000
- 2000-01-10 BG BG104069A patent/BG104069A/en unknown
- 2000-01-11 IS IS5336A patent/IS5336A/en unknown
- 2000-02-08 OA OA1200000030A patent/OA11286A/en unknown
- 2000-02-14 NO NO20000722A patent/NO20000722D0/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HRP980441A2 (en) | 1999-04-30 |
| UY25144A1 (en) | 2000-12-29 |
| WO1999009025A3 (en) | 1999-04-15 |
| IL133960A0 (en) | 2001-04-30 |
| NO20000722L (en) | 2000-02-14 |
| SK1352000A3 (en) | 2000-08-14 |
| CN1265660A (en) | 2000-09-06 |
| IS5336A (en) | 2000-01-11 |
| PE106299A1 (en) | 1999-11-02 |
| ZA987304B (en) | 2000-02-14 |
| OA11286A (en) | 2003-10-22 |
| HUP0003425A2 (en) | 2001-10-28 |
| JP2002536291A (en) | 2002-10-29 |
| EP1003739A2 (en) | 2000-05-31 |
| CO4960656A1 (en) | 2000-09-25 |
| EA200000023A1 (en) | 2000-08-28 |
| NO20000722D0 (en) | 2000-02-14 |
| DZ2583A1 (en) | 2003-02-22 |
| AU8457298A (en) | 1999-03-08 |
| BR9811557A (en) | 2000-08-22 |
| PL338947A1 (en) | 2000-12-04 |
| TR200000414T2 (en) | 2000-08-21 |
| CA2297486C (en) | 2005-05-03 |
| KR20010022507A (en) | 2001-03-15 |
| AP9801321A0 (en) | 2000-02-14 |
| WO1999009025A2 (en) | 1999-02-25 |
| ID23803A (en) | 2000-05-11 |
| MA24632A1 (en) | 1999-04-01 |
| HUP0003425A3 (en) | 2002-02-28 |
| PA8457001A1 (en) | 2000-09-29 |
| TNSN98151A1 (en) | 2005-03-15 |
| BG104069A (en) | 2001-05-31 |
| CA2297486A1 (en) | 1999-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR017019A1 (en) | COMPOUNDS DERIVED FROM 2- (4-ARIL OR HETEROARILPIPERAZIN-1-ILMETIL) -1H-INDOL, COMPOSITIONS AND ITS USE IN THE MANUFACTURE OF MEDICINES | |
| CO4940458A1 (en) | NOVEL INHIBITORS OF N-SUBSTITUTED UREA FOR PROTEIN TRANSFERASE FARNESILO | |
| PE20030976A1 (en) | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | |
| ES2173846T3 (en) | INDOL BICICLOCARBONIL COMPOUNDS AS ANTI-INFLAMMATORY / ANALGESIC AGENTS AND AS COX-2 INHIBITORS. | |
| AR025976A1 (en) | FAB INHIBITORS I. | |
| AR033306A1 (en) | COMPOUNDS | |
| CO5570660A2 (en) | MODIFIED C-6 INDAZOLILPIRROLOTRIAZINAS | |
| CO5310534A1 (en) | NEW ANDROSTAN ANTI-INFLAMMATORY DERIVATIVES | |
| CO5060482A1 (en) | BIARILO THERAPEUTIC DERIVATIVES | |
| CO5560610A2 (en) | DERIVATIVES OF YODOBENZOPIRAN-4-ONA THAT HAVE FUNGICIDE ACTIVITY | |
| NI200800008A (en) | METHODS FOR NEUROPROTECTION | |
| DK0666858T3 (en) | 5-arylindole derivatives and their use as serotonin (5-HT1) agonists | |
| TR200103335T2 (en) | Amine derivatives as protease inhibitors | |
| AR048567A1 (en) | DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS. | |
| DK1473294T3 (en) | Substituted 1,3-oxathiolanes with antiviral properties | |
| DE3868301D1 (en) | 2- (METHYL (4-PIPERIDINYL)) - 1,2,3,4-TETRAHYDRO-9H-PYRIDO (3,4-B) INDOLE DERIVATIVES, THEIR PRODUCTION AND THERAPEUTIC USE. | |
| PE20060298A1 (en) | BENZHIMIDAZOLONE CARBOXYL ACID DERIVATIVES | |
| CY1105091T1 (en) | SUBSTITUTED 2-ARYLOBENZOLE COMPOUNDS AND THEIR USE AS ANTI-TUMOR AGENTS | |
| PE20001583A1 (en) | DERIVATIVES OF 1-ARENOSULFONIL-2-ARYL-PYROLIDINE AND PIPERIDINE | |
| NO20080739L (en) | Methods for Treating Epileptogenesis | |
| PE20040698A1 (en) | ISOINDOLINE DERIVATIVES | |
| AR062405A1 (en) | ISOINDOL DERIVATIVES | |
| AR045793A1 (en) | COMPOUNDS DERIVED FROM 3-HETEROCICLIL-INDOL | |
| MX9806171A (en) | 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors. | |
| AR054083A1 (en) | IMIDAZOL COMPOUNDS AND ITS USE TO PREPARE MEDICATIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |